mitomycin has been researched along with Cancer of Kidney in 84 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Patients (aged ≥18 years) with primary or recurrent biopsy-proven, low-grade upper tract urothelial cancer (measuring 5-15 mm in maximum diameter) and an Eastern Cooperative Oncology Group performance status score of less than 3 (Karnofsky Performance Status score >40) were registered to receive six instillations of once-weekly UGN-101 (mitomycin 4 mg per mL; dosed according to volume of patient's renal pelvis and calyces, maximum 60 mg per instillation) via retrograde catheter to the renal pelvis and calyces." | 6.94 | Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. ( Adibi, M; Amin, MB; Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, S; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Stern, J; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2020) |
| " Bleeding, infection, and fever were most common with adjuvant treatment (BCG or mitomycin)." | 5.12 | Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma. ( Linehan, J; Schoenberg, M; Seltzer, E; Smith, AB; Thacker, K, 2021) |
| " Patients (aged ≥18 years) with primary or recurrent biopsy-proven, low-grade upper tract urothelial cancer (measuring 5-15 mm in maximum diameter) and an Eastern Cooperative Oncology Group performance status score of less than 3 (Karnofsky Performance Status score >40) were registered to receive six instillations of once-weekly UGN-101 (mitomycin 4 mg per mL; dosed according to volume of patient's renal pelvis and calyces, maximum 60 mg per instillation) via retrograde catheter to the renal pelvis and calyces." | 2.94 | Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial. ( Adibi, M; Amin, MB; Chamie, K; Coleman, J; Godoy, G; Gore, JL; Hakim, G; Hu, B; Hubosky, S; Humphreys, MR; Kaimakliotis, H; Klein, I; Kleinmann, N; Knoedler, JJ; Konorty, M; Lerner, SP; Lifshitz, D; Linehan, J; Matin, SF; O'Donnell, M; Pak, R; Pierorazio, PM; Quek, M; Raman, JD; Rivera, M; Scherr, D; Schoenberg, M; Seltzer, E; Shabsigh, A; Smith, AB; Stern, J; Strauss-Ayali, D; Verni, M; Weight, C; Weizer, A; Woods, M, 2020) |
| " Protocol variability and dosage differences limit statistical interpretation." | 2.72 | Nephron-sparing management of upper tract urothelial carcinoma. ( Farrow, JM; Gryzinski, GM; Kern, SQ; Sundaram, CP, 2021) |
| "A recurrence of bladder tumors following surgery for transitional cell carcinoma of the upper urinary tract is not rarely observed." | 2.70 | Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study. ( Ariyoshi, A; Fujisawa, Y; Kumazawa, J; Morita, I; Naito, S; Omoto, T; Osada, Y; Sakamoto, N; Yamashita, H, 2001) |
| "A total of 49 patients with metastatic renal cell cancer underwent recombinant interferon-alpha 2a therapy combined with chemotherapy." | 2.67 | Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer. ( Amato, R; Dexeus, FH; Fitz, K; Kilbourn, R; Logothetis, CJ; Sella, A; Wallace, S, 1992) |
| "Renal cancer is a typical tumor most insensitive to standard chemotherapy, but this hypervascular tumor has an anatomical feature by which its main feeding artery is readily accessible to transarterial targeting treatments." | 2.39 | [Targeting therapy for renal cancer]. ( Kakinuma, H; Kato, T; Sato, K, 1994) |
| " Ureteral stenosis and other adverse events were abstracted from the medical records." | 1.91 | Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma. ( Bjurlin, M; Dickstein, R; Eisner, B; Feldman, A; Ghodoussipour, S; Humphreys, M; Jacob, J; Kaimakliotis, H; Labbate, C; Linehan, J; Lotan, Y; Matin, SF; Murray, K; Nieder, A; O'Donnell, M; Quek, M; Rose, K; Sexton, W; Tachibana, I; Woldu, S, 2023) |
| "Mitomycin C as a treatment for superficial bladder carcinomas and upper urinary tract tumours has been linked to local adverse events." | 1.51 | Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report. ( Castro-Rebollo, P; Marco-Hernandez, J; Rodriguez-Reyes, M; Soy-Muner, D, 2019) |
| "Mitomycin C has limited systemic absorption when given intravesically because of its high molecular weight." | 1.30 | Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma. ( Bagley, DH; Keeley, FX, 1997) |
| "Fresh operative cells from 27 renal cell carcinomas (RCC) were cultured in vitro for the determination of in vitro drug sensitivity." | 1.30 | Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma. ( Baltaci, S; Beksac, M; Küpeli, B; Küpeli, S; Süzer, O, 1997) |
| "Twenty of 22 cases, including 11 of 13 bladder cancer cases, 1 of 3 renal cancer cases, 2 of 3 testicular cancer cases and 1 of 1 adrenal cortical cancer cases, were evaluable in the clinical study of the CGM assay." | 1.29 | [Efficacy of the chemosensitivity test using collagen gel matrix-supported culture system for urogenital tumors]. ( Aikawa, K; Irisawa, C; Ishibashi, K; Ishiwata, H; Koseki, K; Ogihara, M; Shiraiwa, Y, 1996) |
| "Samples of 38 human renal cell carcinomas (RCC) were subjected to routine histopathological examination but also to in vitro sensitivity testing with mitomycin C, vinblastine and interferon Alpha-2a at various concentrations corresponding to serum titers recommended to be effective in vivo, employing a monolayer assay." | 1.28 | In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a. ( Allhoff, E; Anton, P; de Riese, W; Jonas, U; Lenis, G; Liedke, S; Schlick, R; Stief, CG, 1991) |
| "Mitomycin C of 1 mg/kg was administered via a catheter placed into the regional artery." | 1.27 | [Combination of intra-arterial administration of anticancer agent and hemocarboperfusion in treatment of advanced cancer]. ( Agishi, T; Hata, H; Ishigami, J; Kamidono, S; Nagata, T; Ota, K; Shibayama, K; Shida, K; Yamagata, J; Yamanaka, E, 1983) |
| "The kinetic study of hypernephroma cells and normal renal cells showed that the uptake of H3-uridine and H3-thymidine is at its maximum after eighty hours." | 1.27 | In vitro chemosensitivity testing of renal cell cancer. Short-term culture technique. ( Bazeed, MA; Becht, E; Jacobi, GH; Schärfe, T; Schmidt, J; Thüroff, JW, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 30 (35.71) | 18.7374 |
| 1990's | 18 (21.43) | 18.2507 |
| 2000's | 7 (8.33) | 29.6817 |
| 2010's | 18 (21.43) | 24.3611 |
| 2020's | 11 (13.10) | 2.80 |
| Authors | Studies |
|---|---|
| Rosen, GH | 1 |
| Nallani, A | 1 |
| Muzzey, C | 1 |
| Murray, KS | 5 |
| Woldu, SL | 3 |
| Labbate, C | 6 |
| Rose, K | 5 |
| Sexton, W | 5 |
| Tachibana, I | 5 |
| Kaimakliotis, H | 6 |
| Jacob, J | 6 |
| Dickstein, R | 6 |
| Linehan, J | 8 |
| Nieder, A | 5 |
| Bjurlin, MA | 3 |
| Humphreys, M | 5 |
| Ghodoussipour, S | 5 |
| Quek, ML | 3 |
| O'Donnell, M | 6 |
| Eisner, BH | 4 |
| Feldman, AS | 4 |
| Matin, SF | 10 |
| Lotan, Y | 7 |
| Woldu, S | 4 |
| Murray, K | 2 |
| Bjurlin, M | 2 |
| Quek, M | 3 |
| Eisner, B | 1 |
| Feldman, A | 2 |
| Rose, KM | 1 |
| Humphreys, MR | 2 |
| Sexton, WJ | 1 |
| Song, S | 1 |
| Smith, A | 1 |
| Hu, B | 2 |
| Kaimakliotis, HZ | 1 |
| Kleinmann, N | 1 |
| Pierorazio, PM | 1 |
| Gore, JL | 1 |
| Shabsigh, A | 1 |
| Chamie, K | 1 |
| Godoy, G | 1 |
| Hubosky, S | 1 |
| Rivera, M | 1 |
| Raman, JD | 4 |
| Knoedler, JJ | 1 |
| Scherr, D | 1 |
| Stern, J | 1 |
| Weight, C | 1 |
| Weizer, A | 1 |
| Woods, M | 1 |
| Smith, AB | 2 |
| Coleman, J | 1 |
| Pak, R | 1 |
| Lifshitz, D | 1 |
| Verni, M | 1 |
| Adibi, M | 1 |
| Amin, MB | 1 |
| Seltzer, E | 2 |
| Klein, I | 1 |
| Konorty, M | 1 |
| Strauss-Ayali, D | 1 |
| Hakim, G | 1 |
| Schoenberg, M | 2 |
| Lerner, SP | 1 |
| Freifeld, Y | 1 |
| Ghandour, R | 1 |
| Singla, N | 1 |
| Bagrodia, A | 1 |
| Rapoport, LM | 1 |
| Gazimiev, M | 1 |
| Delafuente, K | 1 |
| Kulangara, R | 1 |
| Robyak, H | 1 |
| Petros, FG | 1 |
| Margulis, V | 1 |
| Xu, DD | 1 |
| Ding, M | 1 |
| Tong, P | 1 |
| Chong, YY | 1 |
| Gu, WY | 1 |
| Li, Y | 1 |
| Fang, XJ | 1 |
| Li, N | 1 |
| Thacker, K | 1 |
| Farrow, JM | 1 |
| Kern, SQ | 1 |
| Gryzinski, GM | 1 |
| Sundaram, CP | 1 |
| Metcalfe, M | 1 |
| Wagenheim, G | 2 |
| Xiao, L | 2 |
| Papadopoulos, J | 2 |
| Navai, N | 2 |
| Davis, JW | 2 |
| Karam, JA | 2 |
| Kamat, AM | 2 |
| Wood, CG | 2 |
| Dinney, CP | 2 |
| Somani, BK | 1 |
| Rodriguez-Reyes, M | 1 |
| Marco-Hernandez, J | 1 |
| Castro-Rebollo, P | 1 |
| Soy-Muner, D | 1 |
| Balasubramanian, A | 1 |
| Metcalfe, MJ | 1 |
| Ubrig, B | 1 |
| Roth, S | 1 |
| Boy, A | 1 |
| Nakamura, K | 1 |
| Terada, N | 1 |
| Sugino, Y | 1 |
| Yamasaki, T | 1 |
| Matsui, Y | 1 |
| Imamura, M | 1 |
| Okubo, K | 1 |
| Kamba, T | 1 |
| Yoshimura, K | 1 |
| Ogawa, O | 1 |
| Rouprêt, M | 3 |
| Babjuk, M | 2 |
| Compérat, E | 1 |
| Zigeuner, R | 2 |
| Sylvester, RJ | 1 |
| Burger, M | 1 |
| Cowan, NC | 1 |
| Böhle, A | 1 |
| Van Rhijn, BW | 1 |
| Kaasinen, E | 2 |
| Palou, J | 2 |
| Shariat, SF | 1 |
| Shibing, Y | 1 |
| Qiang, W | 1 |
| Motamedinia, P | 1 |
| Keheila, M | 1 |
| Leavitt, DA | 1 |
| Rastinehad, AR | 1 |
| Okeke, Z | 1 |
| Smith, AD | 2 |
| Lu, DD | 1 |
| Boorjian, SA | 2 |
| Wu, WJ | 1 |
| Ke, HL | 1 |
| Yang, YH | 1 |
| Li, CC | 1 |
| Chou, YH | 1 |
| Huang, CH | 1 |
| Nieder, AM | 1 |
| O'Brien, T | 1 |
| Ray, E | 1 |
| Singh, R | 1 |
| Coker, B | 1 |
| Beard, R | 1 |
| Boehle, A | 1 |
| Sylvester, R | 1 |
| Oosterlinck, W | 1 |
| Goel, A | 1 |
| Paul, S | 1 |
| Smith, P | 1 |
| Mandel, J | 1 |
| Kurzidem, M | 1 |
| Seidensticker, P | 1 |
| Rassweiler, J | 1 |
| Shamash, J | 2 |
| Steele, JP | 1 |
| Wilson, P | 2 |
| Nystrom, M | 1 |
| Ansell, W | 2 |
| Oliver, RT | 1 |
| THIELE, EH | 1 |
| ARISON, RN | 1 |
| BOXER, GE | 1 |
| KOOP, CE | 1 |
| ISHIBASHI, Y | 1 |
| SUGIMURA, K | 1 |
| MYHRE, K | 1 |
| FJAERLI, J | 1 |
| O'Donoghue, JP | 1 |
| Crew, JP | 1 |
| Powles, T | 1 |
| Oliver, T | 1 |
| Nabil, M | 1 |
| Gruber, T | 1 |
| Yakoub, D | 1 |
| Ackermann, H | 1 |
| Zangos, S | 1 |
| Vogl, TJ | 1 |
| Konno, S | 1 |
| Tanaka, J | 1 |
| Urabe, D | 1 |
| Miyazaki, F | 1 |
| Noda, S | 1 |
| Maeda, H | 1 |
| Konno, T | 1 |
| Imray, FP | 1 |
| Smith, PJ | 1 |
| Relf, W | 1 |
| Kidson, C | 1 |
| Crawfurd, MD | 1 |
| Fujihiro, S | 1 |
| Takeuchi, T | 1 |
| Fujimoto, Y | 1 |
| Okano, M | 2 |
| Horie, M | 1 |
| Kanematsu, M | 1 |
| Kuriyama, M | 1 |
| Ban, Y | 1 |
| Nishiura, T | 1 |
| Yamagata, J | 1 |
| Agishi, T | 1 |
| Ota, K | 1 |
| Shida, K | 1 |
| Shibayama, K | 1 |
| Yamanaka, E | 1 |
| Hata, H | 1 |
| Nagata, T | 1 |
| Ishigami, J | 2 |
| Kamidono, S | 2 |
| Kakizoe, T | 1 |
| Matsumoto, K | 2 |
| Nishio, Y | 1 |
| Ohtani, M | 1 |
| Miyazawa, N | 1 |
| Satomi, Y | 1 |
| Takai, S | 1 |
| Nakahashi, M | 1 |
| Furuhata, A | 1 |
| Kato, T | 7 |
| Shindo, M | 1 |
| Machida, T | 1 |
| Masuda, F | 1 |
| Trindade, A | 1 |
| Samuels, ML | 1 |
| Logothetis, CJ | 2 |
| Takano, Y | 1 |
| Oida, K | 1 |
| Kohri, Y | 1 |
| Taguchi, Y | 1 |
| Tomii, K | 1 |
| Matsumura, Y | 1 |
| Mino, M | 1 |
| Gohma, I | 1 |
| Inoue, T | 1 |
| Kobashi, Y | 1 |
| Swanson, DA | 1 |
| Kakinuma, H | 2 |
| Sato, K | 6 |
| Miura, K | 1 |
| Sasaki, S | 1 |
| Eastham, JA | 1 |
| Huffman, JL | 1 |
| Seaman, EK | 1 |
| Slawin, KM | 1 |
| Benson, MC | 1 |
| Weston, PM | 1 |
| Greenland, JE | 1 |
| Wallace, DM | 1 |
| Schulz, WA | 1 |
| Eickelmann, P | 1 |
| Sies, H | 1 |
| Ogihara, M | 1 |
| Aikawa, K | 1 |
| Ishibashi, K | 1 |
| Irisawa, C | 1 |
| Shiraiwa, Y | 1 |
| Koseki, K | 1 |
| Ishiwata, H | 1 |
| Gutman, M | 1 |
| Abu-Abid, S | 1 |
| Sorkine, P | 1 |
| Inbar, M | 1 |
| Lev, D | 1 |
| Chen, Z | 1 |
| Oron, D | 1 |
| Chaitchik, S | 1 |
| Klausner, JM | 1 |
| Keeley, FX | 1 |
| Bagley, DH | 1 |
| Küpeli, S | 1 |
| Beksac, M | 1 |
| Küpeli, B | 1 |
| Baltaci, S | 1 |
| Süzer, O | 1 |
| Sakamoto, N | 1 |
| Naito, S | 1 |
| Kumazawa, J | 1 |
| Ariyoshi, A | 1 |
| Osada, Y | 1 |
| Omoto, T | 1 |
| Fujisawa, Y | 1 |
| Morita, I | 1 |
| Yamashita, H | 1 |
| Mitsumori, K | 1 |
| Uekado, Y | 1 |
| Hirano, A | 1 |
| Shinka, T | 1 |
| Ohkawa, T | 1 |
| Yamada, S | 1 |
| Deguchi, T | 1 |
| Nezasa, S | 1 |
| Tamaki, M | 1 |
| Ehara, H | 1 |
| Kawada, Y | 1 |
| Sella, A | 1 |
| Fitz, K | 1 |
| Dexeus, FH | 1 |
| Amato, R | 1 |
| Kilbourn, R | 1 |
| Wallace, S | 1 |
| Yanagawa, M | 1 |
| Suzuki, S | 1 |
| Kameda, K | 1 |
| Nakano, S | 1 |
| Kinbara, H | 1 |
| Araki, T | 1 |
| Sakurai, M | 1 |
| Hioki, T | 1 |
| Sugimura, Y | 1 |
| Tochigi, H | 1 |
| de Riese, W | 2 |
| Allhoff, E | 1 |
| Stief, CG | 1 |
| Lenis, G | 2 |
| Schlick, R | 1 |
| Liedke, S | 1 |
| Anton, P | 1 |
| Jonas, U | 1 |
| Steven, FS | 1 |
| Griffin, MM | 1 |
| Barnett, FB | 1 |
| Epenetos, AA | 1 |
| Gohji, K | 1 |
| Okada, Y | 1 |
| Hamami, G | 1 |
| Murao, S | 1 |
| Aogauchi, R | 1 |
| Maeda, S | 1 |
| Sugiyama, T | 1 |
| Abe, R | 3 |
| Moriyama, M | 3 |
| Arrizabalaga, M | 1 |
| Casanueva, T | 1 |
| Benítez, J | 1 |
| Escribano, G | 1 |
| Gallardo, C | 1 |
| Streem, SB | 1 |
| Pontes, EJ | 1 |
| Aeikens, B | 1 |
| Schindler, E | 1 |
| van Helsdingen, PJ | 1 |
| Rikken, CH | 1 |
| Hostetter, AL | 1 |
| Tubbs, RR | 1 |
| Ziegler, T | 1 |
| Gephardt, GN | 1 |
| McMahon, JT | 1 |
| Schreiber, MJ | 1 |
| Orihuela, E | 1 |
| Crowley, AR | 1 |
| Nakajima, K | 1 |
| Hisazumi, H | 1 |
| Tokunaga, S | 1 |
| Nitta, M | 1 |
| Nakashima, T | 1 |
| Fuse, H | 1 |
| Saito, Y | 1 |
| Takashima, T | 1 |
| Kojima, A | 1 |
| Annen, Y | 1 |
| Stewart, DJ | 1 |
| Futter, N | 1 |
| Irvine, A | 1 |
| Danjoux, C | 1 |
| Moors, D | 1 |
| Bazeed, MA | 1 |
| Schärfe, T | 1 |
| Becht, E | 1 |
| Schmidt, J | 1 |
| Jacobi, GH | 1 |
| Thüroff, JW | 1 |
| Nakano, E | 1 |
| Tada, Y | 1 |
| Ichikawa, Y | 1 |
| Fujioka, H | 1 |
| Ishibasi, M | 1 |
| Matsuda, M | 1 |
| Takaha, M | 1 |
| Sonoda, T | 1 |
| Mori, H | 1 |
| Tamakawa, Y | 1 |
| Unno, K | 1 |
| Goto, A | 1 |
| Chiba, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma[NCT02793128] | Phase 3 | 71 participants (Actual) | Interventional | 2017-04-04 | Completed | ||
| A Prospective, Open-label Randomized Clinical Trial of a Single Bladder Instillation of Mitomycin C vs. Gemcitabine vs. No Additional Treatment Immediately After Transurethral Resection of Bladder Tumor (TURBT)[NCT02695771] | Phase 3 | 101 participants (Actual) | Interventional | 2016-04-19 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Clinical benefit for patients with partial response (PR) at the PDE visit. Clinical benefit endpoint was analyzed using the Intent-to-Treat (ITT) Analysis Set, including patients who achieved partial response at PDE Visit.Partial response at PDE visit will be defined dichotomously, similarly to the primary efficacy endpoint. For subjects with partial response at PDE visit, originally planned and actual treatments will be compared. (NCT02793128)
Timeframe: An average of 11 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Mitomycin for Pyelocalyceal Solution | 8 |
"Durability of CR defined dichotomously as Success if CR was achieved at Primary Disease Evaluation (PDE) visit and remained at follow-up Visit 1, Visit 2 and Visit 3 (3, 6, 9 and 12 months post PDE visit), and Failure otherwise." (NCT02793128)
Timeframe: 3, 6, 9 and 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Patients Evaluated 3 Months Post PDE | 35 |
| UGN-101 Patients Evaluated at 6 Months Post PDE | 33 |
| UGN-101 Patients Evaluated at 9 Months Post PDE | 28 |
| UGN-101 Patients Evaluated at 12 Months Post PDE | 23 |
"Cmax: maximum plasma concentration~Analysis of individual plasma concentration versus time profiles showed that at 6 hours post instillation, the plasma concentrations of all 6 patients were below 2 ng/mL, with the plasma concentration of one patient dropping below the LOQ (i.e., < 0.100 ng/mL). The mean Cmax was 6.24 ng/mL (range: 2.43 to 12.80 ng/mL). The highest individual observed Cmax value of 12.80 ng/mL was 187-fold and 40 fold lower than the observed Cmax level following an intravenous bolus dose of 30 mg or 10 mg mitomycin (2.4 μg/mL and 0.52 μg/mL, respectively) and is 31 fold lower than the threshold value of 400 ng/mL for myelosuppression observed with mitomycin." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation of UGN-101
| Intervention | ng/mL (Mean) |
|---|---|
| Pharmacokinetic Population | 6.24 |
"Half-life (t½): terminal half-life~The mean apparent t½ following instillation of mitomycin into the upper urinary tract (UUT) was 1.27 hours (76 minutes), which was longer than the true t½ of mitomycin following a 30 mg bolus injection (mean t½ value of approximately 17 minutes). The apparent t½ demonstrates that UGN-101 dissolved gradually, resulting in prolonged exposure of mitomycin following local instillation into the UUT." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation with UGN-101
| Intervention | Hours (Number) |
|---|---|
| Pharmacokinetic Population | 1.27 |
"Tmax: time to maximum plasma concentration~Analysis of individual plasma concentration versus time profiles showed that at 6 hours post instillation, the plasma concentrations of all 6 patients were below 2 ng/mL, with the plasma concentration of one patient dropping below the LOQ (i.e., < 0.100 ng/mL).~The mean Cmax was 6.24 ng/mL (range: 2.43 to 12.80 ng/mL), and the Tmax was 1.79 hours (range: 0.50 to 5.17 hours) after instillation. The highest individual observed Cmax value of 12.80 ng/mL was 187-fold and 40 fold lower than the observed Cmax level following an intravenous bolus dose of 30 mg or 10 mg mitomycin (2.4 μg/mL and 0.52 μg/mL, respectively) and is 31 fold lower than the threshold value of 400 ng/mL for myelosuppression observed with mitomycin." (NCT02793128)
Timeframe: Blood samples were collected at 0 minutes (pre-dose) and 30 minutes, 1, 2, 3, 4, 5, and 6 hours following the first instillation with UGN-101
| Intervention | Hours (Mean) |
|---|---|
| Pharmacokinetic Population | 1.79 |
"Continuously: Duration of CR or time-to-recurrence since the Primary Disease Evaluation (PDE) Visit (i.e., time in days from the visit at which CR was determined until recurrence or censoring). This endpoint served as the main long-term durability endpoint. Dichotomously: Success if CR was still present at the 12 month post-PDE Visit (at Follow-Up Visit 4), and Failure otherwise. This endpoint served as a supportive long-term durability endpoint." (NCT02793128)
Timeframe: 12 months
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Mitomycin for Pyelocalyceal Solution | 23 |
"The primary efficacy endpoint was the number of patients attaining complete response (CR) at the end of the treatment period (Primary Disease Evaluation (PDE) visit). The CR was defined dichotomously as Success if CR was confirmed at PDE visit (or relevant follow-up), and Failure otherwise." (NCT02793128)
Timeframe: An average of 11 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| UGN-101 Mitomycin for Pyelocalyceal Solution | 42 |
Treatment-emergent AEs were most frequently reported from the Renal and urinary disorders system organ class (SOC), 59 (83.1%) patients, as expected, given the underlying indication of low grade (LG) Upper tract urothelial carcinoma (UTUC) in the study population, chemotherapeutic drug in a gel matrix instilled in the upper urinary tract (UUT), and the study procedure of treatment instillation via a ureteral catheter. The toxicity within the upper urinary tract was considered consistent with the disease under study and the mode of administration of UGN-101. Most events in the Renal and urinary disorders SOC were mild to moderate in severity and resolved. No new risks were identified and the overall safety profile was consistent with the known safety profile of endoscopic administration of intravesical mitomycin and of mitomycin. Overall, based on the safety and efficacy results to date, the benefit-risk profile of UGN-101 is favorable for the treatment of LG-UTUC. (NCT02793128)
Timeframe: Through study completion, an average of 15 months
| Intervention | Participants (Count of Participants) | |||||
|---|---|---|---|---|---|---|
| Treatment-emergent Adverse Events (TEAEs) | TEAEs related to study drug | TEAEs related to study procedure | TEAEs related to study drug or preocedure | Serious Adverse Events (SAE) | SAEs related to study drug or procedure | |
| UGN-101 Mitomycin for Pyelocalyceal Solution | 67 | 52 | 55 | 61 | 28 | 19 |
The secondary endpoint for this study will be the number of subjects who did not experience dystrophic calcification or bladder calculi measured by the number of patients with Grade 3 through Grade 5 Adverse Events that are related to study arm, graded according to NCI CTCAE Version 4.03.Version 4.03 (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 24 |
| Gemcitabine | 23 |
| No Intervention | 25 |
The NCI CTCAE Version 4.03 grades adverse events as follows: grade 3 include severe but non-life-threatening consequences that result in hospitalization and/or interventions, including elective radiologic or operative interventions; grade 4 events include life-threatening consequences, such as those requiring urgent reoperation; and grade 5 events result in treatment-related death. (NCT02695771)
Timeframe: Two years
| Intervention | Participants (Count of Participants) |
|---|---|
| Mitomycin C | 15 |
| Gemcitabine | 14 |
| No Intervention | 20 |
8 reviews available for mitomycin and Cancer of Kidney
| Article | Year |
|---|---|
Mitomycin Gel (UGN-101) as a Kidney-sparing Treatment for Upper Tract Urothelial Carcinoma in Patients with Imperative Indications and High-grade Disease.
Topics: Carcinoma, Transitional Cell; Humans; Kidney; Kidney Neoplasms; Mitomycin; Multicenter Studies as To | 2023 |
Complications Associated With Ureteroscopic Management of Upper Tract Urothelial Carcinoma.
Topics: BCG Vaccine; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Fever; Humans; Incidence; Kidney | 2021 |
Nephron-sparing management of upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined | 2021 |
Is cytotoxic chemotherapy effective in the treatment of advanced renal cell carcinoma?
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cisplatin; Clinical Trials as | 1993 |
[Targeting therapy for renal cancer].
Topics: Brachytherapy; Carcinoma, Renal Cell; Chemoembolization, Therapeutic; Humans; Kidney Neoplasms; Male | 1994 |
Treatment options for upper tract transitional-cell carcinoma.
Topics: Administration, Topical; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Human | 1993 |
[Intra-arterial chemotherapy in urological cancer].
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Capsules; Carcinoma, Re | 2002 |
The role of embolization/chemoembolization in the treatment of renal cell carcinoma.
Topics: Carcinoma, Renal Cell; Combined Modality Therapy; Drug Compounding; Embolization, Therapeutic; Human | 1989 |
7 trials available for mitomycin and Cancer of Kidney
| Article | Year |
|---|---|
Primary chemoablation of low-grade upper tract urothelial carcinoma using UGN-101, a mitomycin-containing reverse thermal gel (OLYMPUS): an open-label, single-arm, phase 3 trial.
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Drug Carriers; Drug Compound | 2020 |
Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
Topics: Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neopl | 2011 |
IPM chemotherapy in cytokine refractory renal cell cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Ci | 2003 |
Regional perfusion with hemofiltration (chemofiltration) for the treatment of patients with regionally advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma | 1996 |
Prophylactic intravesical instillation of mitomycin C and cytosine arabinoside for prevention of recurrent bladder tumors following surgery for upper urinary tract tumors: a prospective randomized study.
Topics: Administration, Intravesical; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Antimetabolites, | 2001 |
Results of adjuvant chemotherapy for invasive uroepithelial cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cis | 1992 |
Phase II study of interferon-alpha and chemotherapy (5-fluorouracil and mitomycin C) in metastatic renal cell cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Dr | 1992 |
69 other studies available for mitomycin and Cancer of Kidney
| Article | Year |
|---|---|
Antegrade Instillation of UGN-101 (Mitomycin for Pyelocalyceal Solution) for Low-Grade Upper Tract Urothelial Carcinoma: Initial Clinical Experience.
Topics: Carcinoma, Transitional Cell; Female; Humans; Hydrogels; Kidney Neoplasms; Male; Mitomycin; Ureteral | 2022 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Ureteral | 2023 |
Efficacy and Safety of Mitomycin Gel (UGN-101) as an Adjuvant Therapy After Complete Endoscopic Management of Upper Tract Urothelial Carcinoma.
Topics: Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Constriction, Pathologic; Humans; Kidney Neopl | 2023 |
The patient experience with localized upper tract urothelial cancer.
Topics: Aged; Carcinoma, Transitional Cell; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Patient Outco | 2023 |
The ablative effect of mitomycin reverse thermal gel: Expanding the role for nephron preservation therapy in low grade upper tract urothelial carcinoma.
Topics: Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Nephrons; Retrospective Studies; | 2023 |
Intraoperative prophylactic intravesical chemotherapy to reduce bladder recurrence following radical nephroureterectomy.
Topics: Administration, Intravesical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Femal | 2020 |
Synergistic effects of low‑dose chemotherapy and T cells in renal cell carcinoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cell Line, Tumor; Ch | 2020 |
Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes.
Topics: Administration, Topical; Aged; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemothera | 2017 |
Editorial Comment on: Induction and Maintenance Adjuvant Mitomycin C Topical Therapy for Upper Tract Urothelial Carcinoma: Tolerability and Intermediate Term Outcomes by Metcalfe et al.
Topics: Adjuvants, Immunologic; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Humans; Kidney Neoplas | 2017 |
Interstitial pneumonitis and myelosuppression associated to mitomycin C urinary tract instillations: A case report.
Topics: Aged; Antibiotics, Antineoplastic; Bone Marrow; Female; Humans; Kidney Neoplasms; Lung Diseases, Int | 2019 |
Salvage topical therapy for upper tract urothelial carcinoma.
Topics: Adjuvants, Immunologic; Administration, Topical; Aged; Aged, 80 and over; Antineoplastic Agents; BCG | 2018 |
Topics: Administration, Intravesical; Carcinoma, Transitional Cell; Humans; Kidney Function Tests; Kidney Ne | 2018 |
Novel constant-pressure irrigation technique for the treatment of renal pelvic tumors after ipsilateral ureterectomy.
Topics: Antibiotics, Antineoplastic; Cystectomy; Endoscopy; Humans; Kidney Neoplasms; Kidney Pelvis; Male; M | 2014 |
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherap | 2015 |
Reply to Yan Shibing and Wei Qiang's Letter to the Editor re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
Re: Morgan Rouprêt, Marko Babjuk, Eva Compérat, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update. Eur Urol 2015;68:868-79.
Topics: Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Humans; Kidney Neoplasms; Mitomycin; Neop | 2016 |
The Expanded Use of Percutaneous Resection for Upper Tract Urothelial Carcinoma: A 30-Year Comprehensive Experience.
Topics: Adjuvants, Immunologic; Adult; Age Factors; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; BC | 2016 |
Intravesical chemotherapy use after radical nephroureterectomy: A national survey of urologic oncologists.
Topics: Administration, Intravesical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2017 |
Should patients with primary upper urinary tract cancer receive prophylactic intravesical chemotherapy after nephroureterectomy?
Topics: Administration, Intravesical; Adult; Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma | 2010 |
Editorial comment.
Topics: Administration, Intravesical; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Combined Mo | 2010 |
Postoperative intravesical therapy to prevent bladder tumor recurrence: are we ready to listen yet?
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2011 |
[European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. European Association of Urology Guideline Group for urothelial cell carcinoma of the upper urinary tract].
Topics: BCG Vaccine; Biomarkers, Tumor; Carcinoma, Transitional Cell; Chemotherapy, Adjuvant; Diagnostic Ima | 2012 |
Re: Tim O'Brien, Eleanor Ray, Rajinder Singh, Bola Coker, Ralph Beard, British Association of Urological Surgeons Section of Oncology. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospecti
Topics: Antibiotics, Antineoplastic; Carcinoma; Female; Humans; Kidney Neoplasms; Male; Mitomycin; Nephrecto | 2012 |
Conservative nephron-sparing treatment of upper-tract tumors.
Topics: Administration, Topical; Antineoplastic Agents; BCG Vaccine; Carcinoma, Transitional Cell; Chemother | 2013 |
Renal chemoembolization with mitomycin c/Ethibloc: pharmacokinetics and efficacy in an animal model.
Topics: Animals; Antibiotics, Antineoplastic; Chemoembolization, Therapeutic; Chemotherapy, Cancer, Regional | 2002 |
ONCOLYSIS BY CLOSTRIDIA. III. EFFECTS OF CLOSTRIDIA AND CHEMOTHERAPEUTIC AGENTS ON RODENT TUMORS.
Topics: Adenocarcinoma; Animals; Antimetabolites; Antineoplastic Agents; Aziridines; Bacteriological Techniq | 1964 |
CURRENT MANAGEMENT OF NEPHROBLASTOMA AND NEUROBLASTOMA.
Topics: Antineoplastic Agents; Child; Dactinomycin; Fluorouracil; Infant; Infant, Newborn; Kidney Neoplasms; | 1964 |
CANCER CHEMOTHERAPY (MITOMYCIN-C) FOLLOWED BY BONE MARROW TRANSPLANTATION.
Topics: Bone Marrow Transplantation; Breast Neoplasms; Carcinoid Tumor; Carcinoma, Bronchogenic; Choriocarci | 1964 |
[RENAL SARCOMA IN BOURNEVILLE-PRINGLE'S PHACOMATOSIS: CASE REPORT].
Topics: Humans; Kidney Neoplasms; Mitomycin; Mitomycins; Neoplasms; Nephrectomy; Neurocutaneous Syndromes; P | 1964 |
TREATMENT OF MALIGNANT TUMOURS WITH 5-FLUOROURACIL IN 80 PATIENTS.
Topics: Biomedical Research; Breast Neoplasms; Colonic Neoplasms; Drug Therapy; Esophageal Neoplasms; Female | 1964 |
Adjuvant topical treatment of upper urinary tract urothelial tumours.
Topics: Adjuvants, Immunologic; Antibiotics, Antineoplastic; BCG Vaccine; Carcinoma, Transitional Cell; Chem | 2004 |
Prognostic factors in cytokine-refractory renal cell carcinoma treated with irinotecan, Cisplatin, and mitomycin chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma, Renal Cell; Cisplatin; Cyto | 2005 |
Repetitive transarterial chemoembolization (TACE) of liver metastases from renal cell carcinoma: local control and survival results.
Topics: Adult; Aged; Carcinoma, Renal Cell; Chemoembolization, Therapeutic; Contrast Media; Deoxycytidine; F | 2008 |
[Treatment of malignant renal tumor with intra-arterial administration of oily anticancer drugs].
Topics: Antibiotics, Antineoplastic; Child; Female; Furans; Humans; Infusions, Intra-Arterial; Iodized Oil; | 1984 |
Wilms' tumour: association with cellular sensitivity to mitomycin C in patients and first-degree relatives.
Topics: Adult; Antibiotics, Antineoplastic; Cell Line; Cell Survival; Child; Chromosome Aberrations; Disease | 1984 |
Mutant genes in Wilms' tumour.
Topics: Chromosome Aberrations; Chromosomes, Human, 6-12 and X; Female; Humans; Kidney Neoplasms; Male; Mito | 1984 |
[Chemotherapy of urothelial cancer with vincristine, mitomycin C, bleomycin, tegafur and OK-432].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Combined Modality Therapy; Female; | 1984 |
[Combination of intra-arterial administration of anticancer agent and hemocarboperfusion in treatment of advanced cancer].
Topics: Antibiotics, Antineoplastic; Female; Hemoperfusion; Humans; Infusions, Intra-Arterial; Injections, I | 1983 |
Chemotherapy by bronchial arterial infusion for pulmonary metastases of renal cell carcinoma.
Topics: Adenocarcinoma; Antineoplastic Agents; Carbazilquinone; Doxorubicin; Female; Humans; Infusions, Intr | 1984 |
[Chemotherapy of renal cell carcinoma. 1. MFC therapy].
Topics: Adenocarcinoma; Adult; Aged; Antibiotics, Antineoplastic; Cytarabine; Drug Therapy, Combination; Eva | 1982 |
[Indication and effect of intra-arterial injection of mitomycin microcapsules in the treatment of kidney cancer].
Topics: Adenocarcinoma; Animals; Antibiotics, Antineoplastic; Capsules; Delayed-Action Preparations; Dogs; E | 1982 |
[Renal cell carcinoma].
Topics: Adenocarcinoma; Cytarabine; Drug Therapy, Combination; Fluorouracil; Humans; Kidney Neoplasms; Lung | 1982 |
Chemotherapy of carcinoma of renal pelvis: preliminary report.
Topics: Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Proto | 1981 |
[A case of lung cancer with choroidal metastasis].
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Squamous Cell; Choroid | 1995 |
[Chemoembolization with mitomycin C microcapsules (MMC-mc) in the treatment of bone metastases from prostatic and renal cancer].
Topics: Aged; Bone Neoplasms; Capsules; Chemoembolization, Therapeutic; Female; Humans; Kidney Neoplasms; Ma | 1994 |
Technique of mitomycin C instillation in the treatment of upper urinary tract urothelial tumors.
Topics: Aged; Aged, 80 and over; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Instillati | 1993 |
Role of topical mitomycin C in upper urinary tract transitional cell carcinoma.
Topics: Administration, Topical; Aged; Carcinoma, Transitional Cell; Female; Humans; Kidney Neoplasms; Mitom | 1993 |
Free radicals in toxicology: redox cycling and NAD(P)H:quinone oxidoreductase.
Topics: Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Drug Resistance, Microbial; Free Radicals; Gene | 1996 |
[Efficacy of the chemosensitivity test using collagen gel matrix-supported culture system for urogenital tumors].
Topics: Animals; Antineoplastic Agents; Bleomycin; Carcinoma, Renal Cell; Cisplatin; Collagen; Culture Media | 1996 |
Adjuvant mitomycin C following endoscopic treatment of upper tract transitional cell carcinoma.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; Carcinoma, Transitional Cell; Chemotherapy, Ad | 1997 |
Determination of in vitro drug sensitivity to a panel of cystostatic drugs and interferon alpha-2b in patients with renal cell carcinoma.
Topics: Adult; Aged; Antineoplastic Agents; Bleomycin; Carcinoma, Renal Cell; Cell Division; Cell Survival; | 1997 |
[Study on chemosensitivity test of urogenital tumors by ATP assay].
Topics: Adenosine Triphosphate; Antineoplastic Agents; Doxorubicin; Drug Screening Assays, Antitumor; HeLa C | 1992 |
[A clinical study on renal cell carcinoma].
Topics: Carcinoma, Renal Cell; Female; Humans; Interferon-alpha; Kidney Neoplasms; Lymphatic Metastasis; Mal | 1991 |
In vitro sensitivity testing of human renal cell carcinoma with cytostatic agents and interferon alpha-2a.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Combined Modality Therapy; Dr | 1991 |
Competitive inhibition of a tumour cell surface protease. A rapid technique for in vitro testing of selective targeting systems.
Topics: Agmatine; Aminacrine; Animals; Binding Sites; Binding, Competitive; Biomarkers, Tumor; Carboxylic Es | 1990 |
[Comparative study of chemosensitivity tests of human urogenital tumors between a clonogenic assay and a novel dye exclusion test].
Topics: Antineoplastic Agents; Cell Survival; Cells, Cultured; Cisplatin; Colony-Forming Units Assay; Cyclop | 1985 |
[Massive secondary psoriasiform dermatitis secondary to intravesical administration of mitomycin C].
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma; Drug Eruptions; Humans; Kidney Neoplasms; | 1989 |
Percutaneous management of upper tract transitional cell carcinoma.
Topics: Aged; Carcinoma, Transitional Cell; Electrosurgery; Humans; Kidney Neoplasms; Male; Mitomycin; Mitom | 1986 |
[In vitro sensitivity testing of human kidney tumors to cytostatic drugs with a rapid in vitro test].
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cell Survival | 1986 |
Treatment of urothelial carcinoma of the upper urinary tract following prostatocystectomy with mitomycin C instillation in the ileal loop.
Topics: Aged; Carcinoma, Transitional Cell; Combined Modality Therapy; Humans; Ileum; Kidney Neoplasms; Male | 1986 |
Chronic glomerular microangiopathy complicating metastatic carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Anemia, Hemolytic; Blood Coagulation; Chronic Disease; Female; Hemolyti | 1987 |
[Treatment of renal cell carcinoma invading the inferior vena cava; role of preoperative targeting chemotherapy].
Topics: Adult; Carcinoma, Renal Cell; Humans; Infusions, Intra-Arterial; Kidney Neoplasms; Male; Middle Aged | 1987 |
Percutaneous management of renal pelvic tumors: a treatment option in selected cases.
Topics: Aged; Aged, 80 and over; BCG Vaccine; Carcinoma, Transitional Cell; Combined Modality Therapy; Femal | 1987 |
[Combined treatment of irradiation and 8 MHz radiofrequency hyperthermia with chemoembolization in advanced renal tumor].
Topics: Aged; Carcinoma, Renal Cell; Combined Modality Therapy; Embolization, Therapeutic; Humans; Hyperther | 1987 |
[Bone metastasis from renal cell carcinoma].
Topics: Bone Neoplasms; Carcinoma, Renal Cell; Combined Modality Therapy; Humans; Kidney Neoplasms; Mitomyci | 1987 |
Mitomycin-C and metronidazole in the treatment of advanced renal-cell carcinoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Female; Humans; | 1987 |
In vitro chemosensitivity testing of renal cell cancer. Short-term culture technique.
Topics: Carcinoma, Renal Cell; Cisplatin; Doxorubicin; Drug Screening Assays, Antitumor; Humans; Kidney Neop | 1988 |
Cytotoxic activity of peripheral blood lymphocytes grown with interleukin 2 against autologous cultured tumor cells in patients with renal cell carcinoma: preliminary report.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Carcinoma, Renal Cell; Cells, Cultured; Culture Media; Cyt | 1985 |
[Mitomycin C microcapsules in renal cell carcinoma].
Topics: Antibiotics, Antineoplastic; Capsules; Carcinoma, Renal Cell; Embolization, Therapeutic; Female; Hum | 1985 |